SHR-1826
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for SHR-1826, covering 2025-03-19 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer [Phase 2]